Unstable angina patients treated with percutaneous coronary intervention in the new millennium: What characterizes them?;Pacientes com angina instável tratados por meio de intervenções coronarianas percutâneas no novo milênio: O que os caracteriza?

Arquivos Brasileiros de Cardiologia

Volumn 88, Issue 1, 2007, Pages 24-27

  Peixoto, Daniele Da Silva ^a   Tanajura, Luiz Fernando Leite ^a,b   Amanda, G M R ^a   Centemero, Marinella Patrizia ^a   Chaves, Áurea Jacob ^a   Maia, Júlio De Paiva ^a   Fonseca, Alberto Gomes Taques ^a   E Mattos, Luiz Alberto Piva ^a   Feres, Fausto ^a   Sousa, José Eduardo M R ^a  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^b NONE   (Brazil)

Author keywords

Coronary angioplasty; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; ORAL ANTIDIABETIC AGENT; RAPAMYCIN; TICLOPIDINE; FIBRINOLYTIC AGENT;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; CORONARY STENT; DIABETES MELLITUS; DRUG ELUTING STENT; FEMALE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; UNSTABLE ANGINA PECTORIS; CLASSIFICATION; MIDDLE AGED; RETROSPECTIVE STUDY; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; FEMALE; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STENTS;

EID: 33947426056     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2007000100004     Document Type: Article

References (22)

1. Theroux P, Fuster V. Acute coronary syndromes unstable angina and non-Q-wave myocardial infarction. Circulation. 1998; 97: 1195-206.
2. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. Guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: executive summary and recommendations. J Am Coll Cardiol. 2000; 102: 1193-209.
3. Unstable angina: diagnosis and management. Guideline overview. Agency for Health Care Policy and Research. J Natl Med Assoc. 1994; 86: 649, 710-2.
4. Wallentin L, Lagerqvist B, Kontny F, Stahle E, Swahn E. Outcome at one year after an invasive compared with a non-invasive strategy in unstable-coronary artery disease: the FRISC II invasive randomized trial. Lancet. 2000; 356: 9-16.
5. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med. 2001; 344: 1879-87.
6. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation Rita 3 randomized trial. Lancet. 2002; 360: 743-51.
7. Morice MC, Serruys PW, Sousa JE, Fadajet J, Ban Hayashi E, Perin M, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346: 1773-80.
8. Stone GW, Ellis SG, Cox DA, Hermiller J, Oshaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350: 221-31.
9. Hamm CW, Braunwald E. A classification of unstable angina revisited. Circulation. 2000; 102: 118-22.
10. Smith SC, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines) - executive summary: a report of the American College of Cardiology / American Heart Association task force on practice Guidelines. (Committee to revise the 1993 guidelines for percutaneous Transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Intervention. Circulation. 2001; 103: 3019-41.
11. Mehta SR, Cannon CP, Fox KAA, Wallentin I, Boden WE, Spacek R, et al. Routine versus selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. JAMA. 2005; 293: 2908-17.
12. Neumann FJ, Kastrati A, Pogatsa-Murray G, Mehilli J, Bollwein H, Bestehorn HP, et al. Evaluation of prolonged antithrombotic pretreatment ("Cooling-Off" strategy) before intervention in patients with unstable coronary syndromes. A randomized controlled trial. JAMA. 2003; 290: 1593-9.
13. de Winter RJ, Windhausen F, Cornel JH, Dunselman PH, Janus CL, Bendermacher PE, et al. Early invasive versus selective invasive management for acute coronary syndromes. N Engl J Med. 2005; 353: 1095-104.
14. Mehta SR, Yusuf S, Peters RJG, Bertrand ME, Lewis BS, Natarajan MK, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358: 527-33.
15. CURE Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345: 494-502.
16. Steinhubl SR, Lauer MS, Mukherjee DP, Moliterno DJ, Lincoff AM, Ellis SG, et al. The duration of pretreatment with ticlopidine prior to stentig is associated with the risk of procedure-related non-Q- wave myocardial infarctions. J Am Coll Cardiol. 1998; 32: 1366-70.
17. Steinhubl SR, Berger PB, Mann JT3rd, Fry ET, DeLago A, Wilmer C, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288: 2411-20.
18. Cianflone D, Ciccirillo F, Buffon A, Trani C, Scabbia EV, Finocchiaro ML et al. Comparison of coronary angiographic narrowing in stable angina pectoris, unstable angina pectoris and in acute myocardial infarction. Am J Cardiol. 1995; 76: 215-9.
19. Pinheiro MG, Rabelo Júnior A, de Jesus RS, Nascimento LC, Costa UM. Acute coronary syndromes in the absence of significant coronary artery disease. Arq Bras Cardiol. 2005; 84: 24-8.
20. Sabaté M, Jiménez-Quevedo P, Angiolillo DJ, Gomez-Hospital JA, Alfonso F, Hernandez-Antolin R, et al. Randomized comparison of sirolimus-eluting stent versus standard stent for percutaneous coronary revascularization in diabetic patients: the diabetes and sirolimus-eluting stent (DIABETES) trial. Circulation. 2005; 112: 2175-83.
21. Stone GW, Ellis SG, Cannon L, Mann JT, Greenberg JD, Spriggs D, et al. Comparison of a polymer-based paclitaxel-eluting stent with a bare-metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005; 294: 1215-23.
22. Kaiser C, Brunner-La Rocca HP, Buser PT, Buser PT, Bonetti PO, Osswald S, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real world setting: randomized Basel Stent KostenEffektivitäts trial (BASKET). Lancet. 2005; 366: 921-9.